AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’

AstraZeneca has struck a $1bn (£773m) deal to buy a Belgian biotech company that specialises in cancer immunotherapies, the latest in a string of acquisitions that also yielded positive results for a late-stage rare disease drug on Monday.

EsoBiotec, a small privately held firm, develops in-vivo CAR-T cell therapies that empower the immune system to attack cancers, and could offer many more patients access to cell therapy treatments, provided in minutes rather than weeks.

The deal marks the latest acquisition by AstraZeneca, which is Britain’s biggest listed company valued at £184bn, as the pharmaceutical group continues to expand its global operations. Its share price fell by 1.2% on Monday afternoon.

Read Full Article Here
 
Astra Zeneca by is licensed under flickr

Follow us

Read our latest news on any of these social networks!

Get latest news delivered daily!

We will send you breaking news right to your inbox


Have a tip? Let us know!

Recent Articles

...
Melania Trump makes bombshell $1 billion threat against Hunter Biden after 'inflammatory' Epstein comments

First lady Melania Trump is threatening to sue Hunter Biden for $1 billion after he made the false claim that she was introduced to President Donald Trump by serial pedophile Jeffrey Epstein.

...
Appeals Court rules DOGE can access sensitive federal data

An appeals court ruled on Tuesday that the Department of Government Efficiency (DOGE) can access sensitive federal data of millions of Americans, reversing a temporary injunction that was issued earlier this year.

  • by:
  • Source: People
  • 08/14/2025
...
Popular Grocery Chain Recalls Potentially Contaminated Cheeses Across 9 States

The products, containing Wegmans Medium Camembert Soft Ripened Cheese, are suspected to be contaminated with Listeria

...
Treasury Department confirms US has surpassed $37 trillion in debt

The United States reportedly reached $34 trillion in debt in January 2024, $35 trillion in July 2024, and $36 trillion in November.